Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 15/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15901373 | 0.92 | PLA2G7 (0.46) | PLA2G7P2RX3 | |
| SCHEMBL15901311 | 0.91 | PLA2G7 (0.49) | PLA2G7P2RX3 | |
| SCHEMBL17347950 | 0.90 | PLA2G7 (0.45) | PLA2G7P2RX3 | |
| SCHEMBL17460316 | 0.90 | PLA2G7 (0.46) | PLA2G7 | |
| SCHEMBL15901546 | 0.89 | PLA2G7 (0.49) | PLA2G7 | |
| SCHEMBL17460277 | 0.88 | PLA2G7 (0.47) | PLA2G7GRM2 | |
| SCHEMBL15900888 | 0.85 | PLA2G7 (0.46) | PLA2G7 | |
| SCHEMBL24998498 | 0.84 | PLA2G7 (0.43) | PLA2G7GRM2P2RX3 | |
| SCHEMBL15901478 | 0.84 | PLA2G7 (0.49) | PLA2G7 | |
| SCHEMBL15900997 | 0.84 | PLA2G7 (0.49) | PLA2G7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708330-B2 | 2,3-dihydroimidazol[1,2-C]pyrimidin-5(1-H)-one based ipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-07-18 | — | — | US | disclosed |
| US-20150361082-A1 | 2,3-DIHYDROIMIDAZOL[1,2-C]PYRIMIDIN-5(1-H)-ONE BASED IPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA2) INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361082-A1 | 2,3-DIHYDROIMIDAZOL[1,2-C]PYRIMIDIN-5(1-H)-ONE BASED IPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA2) INHIBITORS | PLA2G4A, PLA2G4C, PLA2G4B | PLA2G7 16/4885GRM2 1299/4885P2RX3 725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.